If that reflects your experience, it's worth knowing that there are now systemic treatment options available in Australia that go beyond topical management, and that the pathway to accessing them is more straightforward than many patients realise.

What moderate-to-severe atopic dermatitis actually is

Atopic dermatitis is not simply dry, sensitive skin. In people with moderate-to-severe disease, it's a systemic inflammatory condition driven by dysregulation of the immune system, specifically an overactive Th2 immune pathway that triggers widespread inflammation, disrupts the skin barrier, and creates a cycle of itch, scratch, and further damage that is difficult to break.

This means that moisturising alone will not resolve it, because emollients address the surface manifestation rather than the underlying driver. They remain helpful, but in moderate-to-severe disease they're managing a symptom, not treating the cause.

It also means that what you're experiencing is not a reflection of how well you're looking after your skin. The inflammatory process is happening below the surface, and it would occur regardless of your skincare routine.

When topicals aren't enough

Topical corticosteroids are effective for short-term management of flares. Topical calcineurin inhibitors offer a steroid-sparing option for sensitive areas. These remain appropriate and useful tools, particularly for mild disease or localised flares.

But if you're using topical steroids repeatedly and still experiencing flares that significantly affect your quality of life, including disrupted sleep, skin that is consistently weeping or bleeding, or difficulty working or socialising, that's a signal that topical management alone isn't controlling your disease. It's worth asking your GP about a referral to a dermatologist and specifically about systemic treatment options.

What's available now

The treatment landscape for moderate-to-severe atopic dermatitis has changed substantially in the last several years.

Dupilumab (Dupixent) is a biologic that targets the IL-4 and IL-13 pathways central to the Th2 inflammatory response in atopic dermatitis. It's administered by subcutaneous injection fortnightly after a loading dose, and available on the PBS in Australia for adults with moderate-to-severe atopic dermatitis who haven't responded adequately to topical treatments. Clinical trial data and real-world evidence show meaningful improvements in skin clearance, itch, and quality of life for most patients.

JAK inhibitors, including upadacitinib (Rinvoq) and abrocitinib (Cibinqo), are a newer class of oral medications that work by blocking specific inflammatory signalling pathways. They're also PBS-listed for moderate-to-severe atopic dermatitis in adults who meet the eligibility criteria, and they offer an oral alternative for patients who prefer not to inject or who haven't responded fully to dupilumab.

Both options require specialist prescription and ongoing monitoring. Your dermatologist will help determine which is more appropriate based on your history, other medications, and disease pattern.

Getting access: the referral and PBS pathway

PBS access for dupilumab and JAK inhibitors requires a specialist prescription. A GP cannot initiate these medications independently. The process typically involves a referral to a dermatologist, a documented trial of topical therapies, and confirmation that your disease meets the severity criteria.

Waiting times for dermatology can be long. If you've been managing significant disease without a specialist review, it's worth requesting a referral sooner rather than later and being explicit with your GP about the functional impact on your day-to-day life.

Specialty pharmacy support for atopic dermatitis 

Dupilumab requires cold chain management from dispensing through to delivery and storage at home. It should be stored in the fridge between 2°C and 8°C, and can be left at room temperature for a short period before administration.

Beyond storage, a specialty pharmacy can help with PBS coordination, injection technique questions, refill timing, and flagging anything in your regimen that may need review. Starting a biologic for a skin condition can feel unfamiliar, and having a pharmacist who knows the medication well makes that transition easier.

How Ace can help

Ace works with dermatologists supporting patients with atopic dermatitis on biologic and systemic therapy. If you've recently been prescribed dupilumab or a JAK inhibitor, we can ensure correct storage, delivery, and dispensing, and make sure you have support throughout your treatment.

Visit https://portal.acepharmacy.com.au to get started or learn more.

This article is for general information only and does not constitute medical advice. Atopic dermatitis management should be guided by your dermatologist or GP based on your individual history and disease severity.